Recommendation ID
MTG70/01
Question

More research or data collection is recommended on Sleepio for people who are eligible for face-to-face cognitive behavioural therapy for insomnia (CBT-I) in primary care. This is because there is limited clinical evidence to show how effective Sleepio is compared with face-to-face CBT-I. A real-world study is suggested to compare the effectiveness of Sleepio with face-to-face CBT-I.

Any explanatory notes
(if applicable)

The committee concluded that more research is needed on the effectiveness of Sleepio as an alternative to face-to-face CBT-I. It noted that there are some studies comparing Sleepio with face-to-face CBT-I, but the evidence is limited. The committee acknowledged the difficulties of carrying out comparative research, given the accessibility issues with face-to-face CBT-I in the NHS. It understood that a study based on real-world evidence that collects clinical and resource use data in a population eligible for face-to-face CBT-I, may be appropriate. It also considered a link between any Sleepio user data and resource use would help address uncertainties in the economic modelling. The committee also agreed that high-quality, non-UK based direct evidence could be acceptable.


Source guidance details

Comes from guidance
Sleepio to treat insomnia and insomnia symptoms
Number
MTG70
Date issued
May 2022

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 31/05/2022